Please ensure Javascript is enabled for purposes of website accessibility

BioNTech Turbocharges COVID-19 Vaccine Development

By Cory Renauer - Mar 16, 2020 at 1:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Collaborations with Fosun Pharma and Pfizer will help BioNTech accelerate the development and commercialization of a potential COVID-19 vaccine.

The development of a vaccine to prevent COVID-19 infection could progress much faster than expected. On Monday, BioNTech SE (BNTX -0.52%) shared more details regarding BNT162, a potential mRNA-based vaccine the German drugmaker has working on in partnership with Pfizer (PFE 2.15%), the University of Pennsylvania, and the Bill and Melinda Gates Foundation.

Project Lightspeed 

On Monday, BioNTech announced a new collaboration with Fosun Pharma to develop BNT162 in China. The company formerly known as Shanghai Fosun Pharmaceutical Group will bring its clinical development capabilities in China to the rest of the team working on the BNT162 program called Project Lightspeed.

Healthcare professional in a biohazard suit.

Image source: Getty Images.

BioNTech plans to begin clinical testing for BNT162 in late April as part of a global development program that spans the U.S., Germany, and China. BioNTech and Fosun have agreed to work jointly on Project Lightspeed in China, but BioNTech's still in discussions with Pfizer.

Not the first

While BioNTech hammers out a deal with Pfizer, another mRNA-based coronavirus vaccine is already surpassing BNT162 on the development timeline. Also on Monday, the National Institutes of Health (NIH) began dosing patients with a coronavirus candidate co-developed by NIH and Moderna (MRNA 2.58%)

Moderna's vaccine candidate is at least a month ahead of BioNTech's, but both are still a long way from becoming available for the public. Investigators generally like to wait an entire year after injecting patients with either a vaccine or a placebo before counting up who gets sick and who doesn't.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
$160.20 (-0.52%) $0.83
Pfizer Inc. Stock Quote
Pfizer Inc.
$52.75 (2.15%) $1.11
Moderna, Inc. Stock Quote
Moderna, Inc.
$159.56 (2.58%) $4.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.